TeselaGen company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Loan | Alive

Total Raised


Last Raised

$250K | 2 yrs ago

About TeselaGen

TeselaGen develops software systems for the large scale production of DNA assemblies and combinatorial libraries.

TeselaGen Headquarter Location

1501 Mariposa St Suite 312

San Francisco, California, 94107,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing TeselaGen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TeselaGen is included in 2 Expert Collections, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.


Biopharma Tech

838 items

TeselaGen Patents

TeselaGen has filed 3 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Genetics
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics



Genetics, Synthetic biology, Molecular biology, Biotechnology, Bioinformatics


Application Date


Grant Date


Related Topics

Genetics, Synthetic biology, Molecular biology, Biotechnology, Bioinformatics



Latest TeselaGen News

07:45 ET A $28.8 Billion Global Opportunity for Synthetic Biology by 2026 - New Research from StrategyR

Mar 3, 2022

News provided by Share this article Share this article SAN FRANCISCO, March 3, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled  "Synthetic Biology - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 19; Released: February 2022 Executive Pool: 6326 Companies: 141 - Players covered include Agilent Technologies, Inc; Amyris, Inc; Arzeda; Atum; Eurofins Genomics Blue Heron LLC; Codexis, Inc; Creative Enzymes; Cyrus Biotechnology, Inc; Editas Medicine, Inc; Eurofins Scientific; GENEWIZ, Inc; GeneWorks Pty Ltd; Genscript Biotech Corporation; Ginkgo Bioworks; Integrated Dna Technologies, Inc; New England Biolabs; Novozymes A/S; OriGene Technologies, Inc; Proterro, Inc; Synthego Corporation; Synthetic Genomics, Inc. (SGI); Synthorx, Inc; TeselaGen Biotechnology Inc; Thermo Fisher Scientific, Inc; Twist Bioscience and Others. Coverage: All major geographies and key segments Segments: Tool (Oligonucleotides & Synthetic DNA, Enzymes, Cloning Technology Kits, Synthetic Cells, Xeno-Nucleic Acids (XNA), Chassis Organism); Technology (Nucleotide Synthesis & Sequencing, Genome Engineering, Microfluidics, Other Technologies); Application (Pharmaceuticals & Diagnostics, Industrial, Food & Agriculture, Environmental, Other Applications) Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Global Synthetic Biology Market to Reach US$28.8 Billion by the Year 2026 Synthetic biology is an interdisciplinary field of research that utilizes a combination of genetics, biology, engineering, computer science, and chemistry for altering the structure and functioning of microorganisms. Synthetic biology is being used in a wide range of applications, including vaccine, diagnostic test, and drug development, and in food, agriculture, and manufacturing industries. Amid the ongoing COVID-19 pandemic, scientists are looking at synthetic biology as a way to speed up the process of vaccine development. For drug discovery, the enhanced accuracy and speed offered by modern synthetic biology tools can help in significantly accelerating drug development as well as reducing expenses. Technology advances in DNA synthesis, nano-liter scale screening, genome engineering, application of in vitro transcription, continuous and cell-free evolution formats, and machine learning and artificial intelligence are expected to widen opportunities for synthetic biology. Synthetic biology market is also expected to benefit immensely from plunging DNA sequencing and DNA synthesis costs. Other factors driving market growth include increase in the number of entities focused synthetic biology research, growing demand for cross-breed animals, growing incidence of oceanic oil spills, increased R&D funding on drug development, and an upsurge in demand for sustainable energy resources such as biofuels. Amid the COVID-19 crisis, the global market for Synthetic Biology estimated at US$10.8 Billion in the year 2022, is projected to reach a revised size of US$28.8 Billion by 2026, growing at a CAGR of 28.1% over the analysis period. Oligonucleotides & Synthetic DNA, one of the segments analyzed in the report, is projected to grow at a 29.5% CAGR to reach US$16.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Enzymes segment is readjusted to a revised 27% CAGR for the next 7-year period. This segment currently accounts for a 22.9% share of the global Synthetic Biology market. The commanding position of the Oligonucleotides & Synthetic DNA segment is attributed to increasing uptake of synthetic RNA, synthetic DNA and synthetic genes that are used in a broad array of applications. Synthetic biology is used to engineer several microbial enzymes such as inulinase, xylanases, laccases, lipases and amylases among others. Synthetic biology tools such as genetic modification, nanotechnology and post translational modification can be used to modify microbial enzymes and enable their widespread application in various industries. The U.S. Market is Estimated at $4.3 Billion in 2022, While China is Forecast to Reach $2.9 Billion by 2026 The Synthetic Biology market in the U.S. is estimated at US$4.3 Billion in the year 2022. The country currently accounts for a 39.8% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$2.9 Billion in the year 2026 trailing a CAGR of 32.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.3% and 27.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 29.3% CAGR while Rest of European market (as defined in the study) will reach US$3.8 Billion by the end of the analysis period. The US and Europe represent the largest markets for synthetic biology propelled by increased investments for promoting research and development activities in the rapidly evolving sector, strong support from government and private organizations, growing awareness, and high demand for synthetic biology-enabled products. Growth in the US is supported by strong investments in research and development. The region is also witnessing a growing interest for using synthetic biology for development of countermeasures against chemical and biological threats. Synthetic biology is also gaining popularity in developing countries such as India and China with research activities promoted and supported by the government. Cloning Technology Kits Segment to Reach $4.6 Billion by 2026 Cloning kits refers to collections of reagents commonly used to perform rapid DNA fragments cloning. Advanced cloning kits based on synthetic biology combine standard DNA components to provide custom vector constructs. In the global Cloning Technology Kits segment, USA, Canada, Japan, China and Europe will drive the 26.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$939.9 Million will reach a projected size of US$4.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$509.7 Million by the year 2026. Personalized Medicine Takes a Notable Leap Forward with Synthetic Biology Synthetic biology and associated developments hold significant potential to facilitate ongoing efforts in the field of personalized medicine that represents a major leap forward for healthcare. Recent developments and discoveries pertaining to synthetic biology are poised to enable novel approaches in this direction. Technological advances like next-generation sequencing, molecular or chemical tools for genome editing, metagenomic assessment of the micro-biome and latest computational methods for predicting protein structures or functions are likely to benefit synthetic biology and favor personalized medicine. A medical condition or disease represents a homeostatic change in the physiology that bears link with the genome. Since the aging process can be categorized as pathology, researchers may increase the lifespan of humans by altering genes. On the other hand, the genetic background holds a critical part in pharmacokinetics, influencing the onset and progress of a disease. Considering the marked difference between an individual genome and the population average, it is nearly impossible to develop a treatment or drug with high efficacy for all. The issue points towards the significance of personalized medicine, with synthetic biology enabling insights into the genome, metagenome and epigenome of desirable person. The information allows development of mechanisms that can intervene in metabolic pathways associated with the person. The use of synthetic biology for personalized medicine is anticipated to also benefit from recent innovations with transformation potential. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on  iOS  or  Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS:

TeselaGen Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

TeselaGen Rank

  • When was TeselaGen founded?

    TeselaGen was founded in 2011.

  • Where is TeselaGen's headquarters?

    TeselaGen's headquarters is located at 1501 Mariposa St, San Francisco.

  • What is TeselaGen's latest funding round?

    TeselaGen's latest funding round is Loan.

  • How much did TeselaGen raise?

    TeselaGen raised a total of $750K.

  • Who are the investors of TeselaGen?

    Investors of TeselaGen include Paycheck Protection Program, Small Business Innovation Research Awards and Baruch Future Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.